Evidence map›Paper›PMID 33566208›Full record

ArticleJournal of bone and mineral metabolism2021

Plasma periostin as a biomarker of osteoporosis in postmenopausal women with type 2 diabetes.

Junyan Li, Xiaohong Niu, Qinqin Si, Qi Song, Miaomiao Jin, Ruijun Zhou, Yan Sun, Jianbo Li, Qingzhong Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of bone and mineral metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Periostin in Osteoporosis and Cardiovascular Disease.Journal of the Endocrine Society · 2023
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Junyan LiChangzhi Medical College Affiliated Heji Hospital, Endocrinology and Metabolism, Changzhi, China.
Xiaohong NiuChangzhi Medical College Affiliated Heji Hospital, Endocrinology and Metabolism, Changzhi, China.
Qinqin SiChangzhi Medical College Affiliated Heji Hospital, Endocrinology and Metabolism, Changzhi, China.
Qi SongChangzhi Medical College Affiliated Heji Hospital, Endocrinology and Metabolism, Changzhi, China.
Miaomiao JinChangzhi Medical College Affiliated Heji Hospital, Endocrinology and Metabolism, Changzhi, China.
Ruijun ZhouChangzhi Medical College Affiliated Heji Hospital, Endocrinology and Metabolism, Changzhi, China.
Yan SunChangzhi Medical College Affiliated Heji Hospital, Endocrinology and Metabolism, Changzhi, China.
Jianbo LiDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. ljbzjlx18@aliyun.com.
Qingzhong WangShanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. wangqingzhong3@gmail.com.ORCID http://orcid.org/0000-0001-7472-996X
Changzhi Medical College · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPeriostin, as an emerging biomarker, is involved in multiple steps in bone metabolism. This study aimed to investigate the correlation between periostin levels and bone mineral density as well as bone turnover markers in postmenopausal women with type 2 diabetes (T2DM). MATERIALS AND

methodsThis study was a cross-sectional study that included 164 postmenopausal women with T2DM as study subjects and 32 age-matched nondiabetic postmenopausal women with normal bone mineral density (BMD) as healthy control subjects. A total of 164 subjects with T2DM were then divided into three groups according to BMD: the normal BMD group (n = 29), the osteopenia group (n = 70), and the osteoporosis group (n = 65). The clinical data of all subjects along with the relevant biochemical parameter data were collected. Plasma periostin was detected using an enzyme-linked immunosorbent assay (ELISA).

resultsPlasma periostin levels were significantly increased in T2DM patients with normal BMD compared with healthy controls (p < 0.05). In the diabetic group, plasma periostin levels were significantly elevated with decreased BMD, were positively correlated with osteocalcin levels (r = 0.162, p = 0.039) and were inversely associated with femoral neck BMD (r = - 0.308, p < 0.001) and total femur BMD (r = - 0.295, p < 0.001). In the case of chronic complications, periostin levels were slightly increased in individuals with complications of diabetic retinopathy, diabetic nephropathy and fracture (p > 0.05).

conclusionsThe current study demonstrated that plasma periostin levels were significantly associated with BMD in patients with T2DM, and periostin might act as a novel biochemical marker of osteoporosis in postmenopausal women with type 2 diabetes.

Indexed as

Absorptiometry, PhotonBiomarkersBone DensityBone RemodelingCell Adhesion MoleculesCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleHumansMiddle AgedOsteoporosis, PostmenopausalBiomarkersCell Adhesion MoleculesPOSTN protein, humanBone mineral densityOsteoporosisPeriostinPostmenopauseType 2 diabetes

Identifiers

PMID33566208
OpenAlexW3128925546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.